FDA Priority Review: Genentech`s Inavolisib For PIK3CA+ Breast Cancer
29 May 2024 //
BUSINESSWIRE
FDA Priority Review: Roche`s Inavolisib For PIK3CA+ Breast Cancer
29 May 2024 //
GLOBENEWSWIRE
FDA Grants Genentech`s Inavolisib Breakthrough For PIK3CA Breast Cancer
21 May 2024 //
BUSINESSWIRE
FDA Grants Roche`s Inavolisib Breakthrough Therapy For PIK3CA Breast Cancer
21 May 2024 //
GLOBENEWSWIRE